^
    8d
    A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Jecho Biopharmaceuticals Co., Ltd.
    New P1/2 trial
    11d
    A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=17, Completed, Jecho Biopharmaceuticals Co., Ltd.
    New P1 trial
    |
    PVR (PVR Cell Adhesion Molecule)
    13d
    PED-DNX2401: Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Clinica Universidad de Navarra, Universidad de Navarra | N=20 --> 39
    Enrollment change
    |
    tasadenoturev (DNX-2401)
    13d
    A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Shanghai Virogin Biotech Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    22d
    BOND-003: Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (clinicaltrials.gov)
    P3, N=190, Active, not recruiting, CG Oncology, Inc. | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Dec 2027 --> Jun 2030
    Trial completion date • Trial primary completion date
    |
    cretostimogene grenadenorepvec (CG0070)
    22d
    A Study on the Novel Oncolytic Virus Combined With PD-1 Inhibitor in the Treatment of Recurrent High-grade Glioma (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Beijing Bio-Targeting Therapeutics Technology Co., Ltd
    New P1 trial
    27d
    INTRATUMORAL DNX-2401 ADMINISTRATION FOR RECURRENT AND REFRACTORY HIGH GRADE BRAIN TUMORS IN PEDIATRIC AND YOUNG ADULT PATIENTS (2024-515009-24-00)
    P1/2, N=20, Not yet recruiting, Clinica Universidad De Navarra
    New P1/2 trial
    |
    tasadenoturev (DNX-2401)
    1m
    Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling. (PubMed, J Immunother Cancer)
    Overall, the data demonstrate that RP1 remodels the tumor microenvironment through a combination of direct and indirect effects on both tumor and immune cells, resulting in an overall more inflamed phenotype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STING (stimulator of interferon response cGAMP interactor 1) • CSF2 (Colony stimulating factor 2) • ITGAM (Integrin, alpha M) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    PD-L1 expression
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)
    1m
    Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    tasadenoturev (DNX-2401)
    1m
    Bevacizumab-Primed Vascular Normalization Enhances Intratumoral Delivery and Efficacy of the tBID-Armed Oncolytic Adenovirus KD01 in Glioma. (PubMed, Front Biosci (Landmark Ed))
    KD01 exerts potent tBID-mediated mitochondrial oncolytic activity against glioma cells. When used as a priming strategy, transient vascular normalization induced by bevacizumab enhanced the intratumoral efficacy of KD01 in an orthotopic glioma model while maintaining a favorable safety profile. These findings support a simple, sequence-dependent combination approach integrating anti-VEGF therapy with oncolytic virotherapy for the treatment of malignant gliomas.
    Journal
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • BID (BH3 Interacting Domain Death Agonist) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Avastin (bevacizumab)
    1m
    MCC-20575: Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC (clinicaltrials.gov)
    P1, N=21, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    Opdivo (nivolumab) • cretostimogene grenadenorepvec (CG0070)
    1m
    ARTACUS: Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Replimune Inc. | N=65 --> 90 | Trial completion date: Jan 2028 --> Nov 2029 | Trial primary completion date: Sep 2027 --> Jul 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Tudriqev (vusolimogene oderparepvec-wtpg)